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ABSTRACT: Allergic diseases are characterized by allergic complaints in the shock
organ and specific immunoglobulin (Ig)E in serum. Literature data indicate that the
nasal mucosa itself could produce at least a large part of the specific IgE in allergic
rhinitis patients.
In order to investigate this hypothesis, nasal mucosal biopsies from the inferior
turbinate were taken from symptomatic grass pollen allergic rhinitis patients, symp-
tomatic house dust mite allergic rhinitis patients and nonallergic healthy controls,
confirmed by radioallergosorbent test and skin-prick test. Immunohistochemical
double-staining was performed for B-cells (CD19) with IgE, plasma cells (CD138)
with IgE and plasma cells with biotinylated allergens.
Significantly more IgE-positive B-cells and IgE-positive plasma cells were found in
the nasal mucosa of allergic patients than in that of nonallergic controls. Double
staining with biotinylated allergens and plasma cells showed allergen-positive plasma
cells in the nasal mucosa of allergic patients and no allergen-positive plasma cells in
the nasal mucosa of nonallergic patients. Blocking experiments using polyclonal anti-
bodies directed against IgE showed a significant reduction in the number of allergen-
positive cells in contrast to experiments using polyclonal antibodies directed against
IgG, IgA or IgM.
This study describes new evidence that specific immunoglobulin E is produced
locally in the nasal mucosa in patients with seasonal allergic rhinitis and perennial
allergic rhinitis, but not in nonallergic controls.
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To date, it has not been known where the production of
specific immunoglobulin (Ig)E takes place in allergic
rhinitis patients. Some studies have suggested that the
nasal mucosa itself is able to produce at least a large part of
the IgE [1±5]. HUGGINS and BROSTOFF [6] reported patients
who had specific IgE in their nasal secretions and no
detectable levels of specific IgE in their serum. In addi-
tion, specific IgE is present on cells in the nasal mucosa
[7]. The nasal mucosa itself contains all the cell types
(dendritic cells, T-cells and B-cells [8] ) and cytokines
(interleukin (IL)-4 and IL-13 [9±12]) necessary for an IgE
immunoresponse. Other studies have suggested that IgE
synthesis takes place in the downstream cervical lymph
nodes [13, 14] or upper respiratory and lower respiratory
lymph nodes [15]. However no information has been
obtained as to whether the IgE comes from the circulation
(transudate) or from the mucosal glands (exudatate).
ZURCHER et al. [16] demonstrated that functional B-
cells, isolated from the nose and cultured in a CD40-
stimulating system, could synthesize IgE. DURHAM et al.
[17] reported that local allergen provocation induces e
germline transcripts in nasal B-cells. They were not able
to detect IgE-positive B-cells. PAWANKAR et al. [18] sug-
gested novel and critical roles for mast cells obtained
from allergic rhinitis patients in amplifying IgE produc-
tion, within the local microenvironment of the nasal
mucosa.
In this study, the possibility of determining the presence
of IgE-positive B-cells, IgE-positive plasma cells and aller-
gen-binding plasma cells in the nasal mucosa of seasonal
allergic rhinitis patients, perennial allergic rhinitis patients
and nonallergic healthy controls was investigated. Double-
staining experiments were performed to verify whether all
allergen-positive cells were also positive for IgE. Blocking
experiments using polyclonal antibodies directed against
Igs were performed to analyse the specificity of the
allergen-binding cells for IgE.
Materials and methods
Patients and controls
Nasal biopsy (2.5 mm) was performed using Gerritsma
forceps [19]. Twelve grass pollen allergic rhinitis patients
(six male/six female), median age 30 yrs (range 15±45
yrs), with a history of clear seasonal rhinitis for 2 yrs and
a skin-prick test with a reaction of 3+ for grass pollen and
a radioallergosorbent test (RAST) score median of 4+
(range 3+±5+) for grass pollen. The biopsy samples from
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the seasonal grass pollen allergic rhinitis patients were
taken during the grass pollen season. Sixteen perennial
allergic rhinitis patients (10 male/six female) median age
25 yrs range 18±51 yrs) yielded a positive skin-prick test
for house dust mite (HDM), 3+, and a RAST score
median of 3+ (range 3+±5+) for Dermatophagoides pter-
onyssinus. Patients had to have two or more symptoms of
perennial rhinitis (nasal blockage, rhinorrhoea, sneezing)
and to have required medication for perennial rhinitis for
1 yr. The biopsy samples from the perennial allergic
rhinitis patients were taken between October and January
(inclusive) during the HDM season. The control biopsy
samples were taken from twelve healthy volunteers
(seven male/five female), median age 36 yrs (range 18±62
yrs) without nasal complaints or nasal abnormalities on
ear, nose and throat examination and a negative RAST.
None of the patients had structural nasal abnormali-
ties, undergone nasal surgery in the past 6 months, acute
respiratory or sinus infection, serious or unstable concur-
rent disease, proven allergy for an other relevant inhalant
allergen, undergone treatment with systemic or inhaled/
intranasal corticosteroids or inhaled/intranasal sodium cro-
moglycate in the preceding month or used astemizole in
the previous 6 weeks.
The study was approved by the Ethics Committee. All
patients gave informed written consent.
Allergens
The allergens were covalently bound to a soluble
polymer/copolymer matrix labelled with biotin (Diagnostic
Products Corporation, Apeldoorn, the Netherlands) [20].
GP1 (50 mg.mL-1), a mixture of biotinylated grass pollen
(orchard Kentucky, blue, rye and timothy grasses), and
D1 (20 mg.mL-1) biotinylated HDM were used.
Blocking experiment
In order to determine whether the allergen binding was
specific to IgE, cryostat sections were preincubated with
blocking polyclonal antibodies directed against IgA, IgE,
IgG, and IgM (5 mg.mL-1) central laboratory of the Neth-
erlands Red Cross blood transfusion service (CLB), the
Netherlands) and phosphate-buffered saline (PBS, pH 7.8),
followed by the normal allergen staining procedure. These
polyclonal antibodies blocked the cell-bound antibodies of
different types. The blocking was based on spheric
hindrance or the idiotypes of the antibodies were masked,
so that the allergen could not bind. In order to determine
the amount of blocking, the number of allergen- positive
cells were counted and the signal intensities ranked in a
blinded fashion.
Staining procedure
The antibodies used for the staining procedure are
detailed in table 1. Frozen sections (6-mm thick) were
fixed in acetone for 10 min at room temperature (22C)
and rinsed in PBS (pH 7.8). Endogenous peroxidase
blocking was carried out by means of treatment for 30
min in 1% sodium azide and 0.01% hydrogen peroxide in
PBS. The slides were then placed in a semi-automatic
stainer (Sequenze; Shandon, Amsterdam, the Nether-
lands).
Double staining plasma cells or B-cells and immuno-
globulin E
The sections were subsequently incubated for 10 min
with PBS containing bovine serum albumin (BSA, 1%),
normal goat serum (10%), and normal rabbit serum (10%)
(CLB, Amsterdam, the Netherlands) and then for 60 min
with the antibodies to CD138 (plasma cells syndican I; Se-
rotec (Diagnostic Products Corporation, the Netherlands).
They were then rinsed with PBS for 5 min, incubated with
biotinylated goat antimouse (Biogenix, (Klinipath, Duiven,
the Netherlands)) for 30 min, rinsed once more with PBS
for 5 min, incubated with alkaline phosphatase-conjugated
streptavidin (Biogenix, (Klinipath) for 30 min, rinsed with
PBS for 5 min, and incubated for 60 min with FITC-
conjugated rabbit antihuman IgE. After rinsing with PBS,
they were incubated for 30 min with peroxidase-con-
jugated rabbit-anti FITC (Dako (ITK, Uithoorn, the Neth-
erlands)). Finally, the slides were rinsed with PBS and
tris-hydroxymethyl-aminomethane (Tris) (0.2 M, pH 8.5)
for 5 min each, incubated for 10 min with 1.0 mM Fast
Table 1. ± Antibodies used to stain biopsy specimens
Antibody Concentration
mg.mL-1 dilution
Source
Anti CD19 1.3 Immunotech (Coulter, the Netherlands)
Anti CD138 (plasma cells syndican I) 1 Serotec (DPC, Apeldoorn, the Netherlands)
FITC-labelled anti-IgE 50 CLB (Amsterdam, the Netherlands)
Biotinylated grass pollen 50 DPC
Biotinylated der PI 20 DPC
Biotinylated goat antimouse 1:50 Biogenix (Klini Path, Duiven, the Netherlands)
Alkaline phosphatase/peroxidase-labelled streptavidine 1:50 Biogenix (Klini Path)
Alkaline phosphatase-labelled goat antibiotin 1:50 Sigma (the Netherlands)
Alkaline phosphatase-labelled streptavidine/biotin complex 1:50 Vector (Brunschwig Chemie, the Netherlands)
Peroxidase-labelled rabbit anti-FITC 1:50 Dako (ITK, Uithoorn, the Netherlands)
Peroxidase-labelled rabbit antimouse peroxidase 1:100 Sigma
Peroxidase-labelled mouse antiperoxidase 1:100 Sigma
IgE: immunoglobulin E; FITC: fluorescein isothiocyanate; DPC: Diagnostic Products Corporation; CLB: central laboratory of the
Netherlands Red Cross blood transfusion service.
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Blue substrate, rinsed with sodium acetate (0.2 M, pH 4.6)
for two periods of 5 min, incubated with 1% 3-amino-9-
ethylcarbazole (AEC) for 30 min, rinsed in distilled water
and mounted in glycerine/gelatin (1:1).
Double staining immunoglobulin E and biotinylated
allergen
The sections were subsequently incubated for 10 min
with PBS containing BSA (0.5±1%), normal rabbit serum
(10%) and normal goat serum (10%) (CLB), followed by
100 min with biotinylated allergen (AlaSTAT, DPC) [7]
and thereafter for 60 min with the polyclonal antibodies
to IgE. They were then rinsed with PBS for 5 min, incu-
bated with alkaline phosphatase-conjugated goat-anti-
biotin (Sigma) for 30 min After rinsing with PBS, they
were incubated for 30 min with peroxidase-conjugated
rabbit anti-FITC (Dako, (ITK), Uithoorn, the Nether-
lands). Finally, the samples were rinsed with PBS for 5
min, rinsed with Tris (0.2 M, pH 8.5) for 5 min, incubated
for 10 min with 1.0 mM Fast Blue substrate, rinsed with
sodium acetate (0.2 M, pH 4.6) for two periods of 5 min,
incubated with AEC for 30 min, rinsed in distilled water
and mounted in glycerine/gelatin (1:1).
Double staining plasma cells and biotinylated allergen
The sections were subsequently incubated for 10 min
with PBS containing BSA (0.5±1%) and normal rabbit ser-
um (10%) (CLB), followed by 60 min with the antibodies
to plasma cells and thereafter for 100 min with biotinylated
allergen. They were then rinsed with PBS for 5 min,
incubated with peroxidase-conjugated Rabbit antimouse
(Sigma) for 30 min, rinsed once more with PBS for 5 min
and incubated with peroxidase-conjugated mouse antiper-
oxidase for 30 min. They were then rinsed with PBS for 5
min, and incubated with alkaline phosphatase-conjugated
goat antibiotin (Sigma) for 30 min. Finally, the samples
were rinsed with PBS for 5 min, rinsed with Tris buffer
(0.2 M, pH 8.5) for 5 min, incubated for 10 min with 1.0
mM Fast Blue substrate, rinsed with sodium acetate (0.2
M, pH 4.6) for two periods of 5 min, incubated with AEC
for 30 min, rinsed in distilled water and mounted in
glycerine/gelatin (1:1).
Controls
The controls used were biopsy sections from nonallergic
patients and those stained immunohistochemically with
irrelevant mouse IgG subclasses. In these sections, no posi-
tivity, nonspecific binding of the conjugates or endogenous
enzyme activity were found.
Statistical analysis
The blocking experiments were analysed using the Fried-
man two-way analysis of variance (ANOVA) test. The dis-
tribution of cells in the epithelium and in the lamina propria
was not symmetrical and the variances were unequal. For
statistical analysis, Kruskal-Wallis one-way ANOVA was
used to calculate the overall p-value. A p-value of <0.05
was considered to indicate a significant difference between
groups of nasal mucosal biopsies. The nonparametric
Mann-Whitney U-test was performed to analyse each
group with respect to each other.
Results
Blocking experiment via preincubation with polyclonal
antibodies
In nasal mucosal sections from mite allergic patients
(n=6) and grass pollen allergic patients (n=10), the number
of allergen-positive cells was always lower after pre-
incubation with polyclonal antibodies directed against IgE
(p<0.0005, Friedman two-way ANOVA). The intensity of
the signal was also decreased by preincubation with anti-
bodies directed against IgE. No significant effect was seen
after preincubation with the other Igs or PBS on the
number of allergen-positive cells or the intensity of the
specifically stained cells (fig. 1).
Immunohistochemical staining
Single staining. The number of IgE-positive cells.mm2
section of nasal mucosa is given in table 2 for the epi-
thelium and lamina propria. No IgE-positive cells were
observed in the epithelium of healthy control biopsy
samples. Significantly (10 fold) more IgE-positive cells
were found in the nasal mucosa of allergic patients (grass
pollen or mite allergic patients) than in healthy nonallergic
control subjects. No differences were observed in the
numbers of B-cells (CD19) or CD138-positive cells (plas-
ma cells). Allergen-positive cells were found in allergic
patients only, not in controls. GP1-positive cells were only
found in patients with only grass pollen allergy. D1-posi-
tive cells were only found in the nasal mucosa of patients
with perennial allergic rhinitis (allergic to HDM). No
allergen-positive cells were found in nonallergic controls.
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Fig. 1. ± Blocking experiments using polyclonal antibodies directed
against immunoglobulin (Ig) E (&) showed a significant reduction in
allergen-positive cells in contrast to those using polyclonal antibodies
directed against IgG (h), IgA (m) or IgM (¨) and phosphate-buffered
saline (s). Biopsy samples from each patient house dust mite (HDM),
n=6; grass pollen, n=10) are plotted separately.
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Double staining. Immunoglobulin E-positive B-cells. Dou-
ble staining with polyclonal antibodies directed against
IgE and monoclonal antibodies directed against B-cells
resulted in the easy identification of red IgE-positive cells,
blueB-cells andmixed-colour (redandblue) IgE-positiveB-
cells (fig. 2a). In two of the controls, no IgE-positive B-cells
were found in the lamina propria. Allergic patients were
found to have four times as many IgE-positive B-cells in
the lamina propria (p<0.02) than nonallergic controls.
Grass pollen allergic patients had significantly more IgE-
positive B-cells in the epithelium (p<0.02) and in the
lamina propria (p<0.05) than nonallergic controls. Peren-
nial (mite) allergic patients were found to have more IgE-
positive B-cells (p<0.05) in the lamina propria than
nonallergic controls. No significant differences were ob-
served between hay fever patients and perennial mite
allergic patients (fig. 3a).
Immunoglobulin E-positive plasma cells. Double staining
with polyclonal antibodies directed against IgE and mono-
clonal antibodies directed against plasma cells resulted in
the easy identification of red IgE-positive cells, blue plasma
cells and mixed-colour (red and blue) IgE-positive plasma
cells (fig. 2b). Plasma cells were only evaluated in the
lamina propria because CD138 is also expressed weakly
in epithelial cells (fig. 2b). Cells positive for IgE alone,
IgE-positive plasma cells and non-IgE-positive plasma
cells were found in allergic patients as well as in non-
allergic controls. However, in seven of the controls, no
IgE-positive plasma cells were found. In the lamina pro-
pria of the nasal mucosal biopsies from allergic patients,
significantly eight-fold (p<0.0007) more IgE-positive
plasma cells were present than in biopsy samples from
nonallergic controls (fig. 3b).
Immunoglobulin E-positive allergen positive cells. IgE-
positive cells stained red, the allergen-positive IgE-positive
cells stained mixed red/blue and hardly any cells positive
for allergen alone (blue, if present) were found. All aller-
gen-positive cells were also positive for IgE, except in one
of the grass pollen allergic patients (median 100% (range
71±100%) and one of the mite allergic patients (median
100% (range 96±100%)).
Allergen positive plasma cells. Double staining was per-
formed using biotinylated allergens (blue) and antibodies
a)
b)
c) d)
Fig. 2. ± Photomicrographs of four nasal mucosal biopsy sections ob-
tained from allergic patients, and double stained immunohistochemi-
cally with antibodies directed against immunoglobulin (Ig) E (red) and:
a) B-cells (blue) (arrows indicate IgE-positive B-cells) and ; b) plasma
cells (blue) (arrows indicate IgE-positive plasma cells); and c, d) double
staining using biotinylated allergens (blue) and antibodies directed ag-
ainst plasma cells (red) (arrows indicate allergen-positive plasma cells).
(Internal scale bars=36 mm(a±c); 72 mm (d).)
Table 2. ± Number of cells found in the nasal mucosa of grass pollen allergic patients, perennial allergic patients and
healthy controls
Cell type Seasonal allergics Perennial allergics Controls ANOVA p-value*
Epithelium
IgE-positive cells 4(1±41) 14 (2±32) 0 (0±0) 0.0003
CD19 (B-cells) 0 (0±0) 0 (0±6) 0 (0±3) 0.2
IgE-positive B-cells 0 (0±1) 0 (0±0) 0 (0±0) 0.05
Lamina propria
IgE-positive cells 417 (273±590) 209 (97±330) 22 (7±37) 0.0001
CD19 (B-cells) 225 (144±293) 152 (81±233) 142 (114±203) 0.2
Plasma cells 43 (18±100) 78 (60±113) 122 (46±151) 0.06
Allergen-positive cells 45 (32±85) 30 (16±57) 0 (0±0) 0.0000
IgE-positive B-cells 8 (4±16) 6 (3±13) 1 (1±5) 0.02
IgE-positive plasma cells 8 (3±18) 9 (6±16) 0 (0±6) 0.0007
Allergen-positive plasma cells 5 (3±8) 2 (2±7) 0 (0±0) 0.0000
*: Kruskal-Wallis one way analysis of variance. Data are presented as median (interquartile range).
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directed against plasma cells red. The allergen-positive cells
generally showed a membrane-staining pattern, with the
allergen bound on the surface of the cell. However, another
staining pattern was found for the allergen-positive plasma
cells, which also showed blue staining in and around the cell
(fig. 2c). This pattern of staining was observed in all grass
pollen allergic patients. However, in two of the mite
allergic patients, no allergen-positive plasma cells were
found.
Discussion
Local production of specific IgE in the nasal mucosa has
been hypothesized by several authors [1±5]. DURHAM et al.
[21] recently described the expression of e germ line gene
transcripts indicating isotype-switching B-cells and an in-
crease in the level of messenger ribonucleic acid (mRNA)
encoding the heavy chain of IgE in nasal B-cells in the
nasal mucosa after local allergen provocation. ZURCHER et
al. [16] demonstrated the possibility of IgE synthesis by
nasal epithelial B-cells; functional B-cells can be isolated
from the nose, and, after stimulation with IL-4 and anti-
bodies directed against CD40, IgE-protein synthesis could
be induced. DIAZ-SANCHEZ et al. [22] also found IgE-pro-
ducing B-cells and mRNA encoding IgE in nasal lavages
fluid from allergic rhinitis patients.
In this biopsy study, the production of IgE by B-cells
and plasma cells in vivo was evaluated in naturally pro-
voked allergic rhinitis patients. This study showed signifi-
cantly more IgE-positive B-cells and IgE-positive plasma
cells in allergic patients than in nonallergic controls. IgE-
positive B-cells and plasma cells were also observed in
healthy controls. An explanation for these IgE-positive cells
could be the smoking of some of the patients, (environ-
mental) tobacco smoke increases the number of IgE-posi-
tive cells [23, 24]. The allergen-positive plasma cells
(specific IgE) were observed only in allergic patients, in
accordance with previous observations of allergen-posi-
tive cells occurring only in the nasal mucosa of allergic
rhinitis patient and not in nonallergic controls [7]. The
observation of the presence of allergen-positive plasma
cells and the finding that all allergen-positive cells were
also IgE-positive indicate that the local production of
allergen-specific IgE takes place in the nasal mucosa.
Blocking experiments showed that the binding was spe-
cific for IgE but not for IgG, IgA or IgM, meaning that
specific IgE is the critical factor for allergen binding to
cells and that this binding was not based on the allergen
binding to IgG, IgA or IgM. IgE antibodies remain firmly
fixed to mast cells for an extended period. IgA antibodies
function by inhibiting the adherence of coated micro-
organisms to the surface of mucosal cells, thereby pre-
venting entry into the body tissues. IgG has properties
with respect to the neutralization of bacterial toxins and
binding to microorganisms to enhance their phagocytosis.
The locally-produced IgA or IgG levels were not high
enough to neutralize the allergen binding to specific IgE-
positive cells.
In a previous study, it was observed that monoclonal
antibodies directed against IgE recognize >80% of all
allergen-positive cells [7]; the present study used rabbit
polyclonal antibodies directed against IgE, and showed
that all allergen-positive cells were also IgE-positive. The
significantly higher number of IgE-positive B-cells in the
nasal mucosa of allergic patients compared to the nasal
mucosa of nonallergic controls and the observation of no
difference in numbers of B-cells expressing CD40 (data
not shown) are an indication that, the e germ line switches
to IgE-positive B-cell early in life. These switched B-cells
require only IL-4 to respond with persistent IgE formation
[25]. The significantly higher numbers of IgE-positive
plasma cells in the allergic nasal mucosa compared to the
controls suggests that the maturation of IgE-positive B-
cells to IgE-producing plasma cells takes place locally in
the nasal mucosa. B-cells express CD 40 during the mat-
ure/activated stage [26]. It is not possible to differentiate
between IgE-positive B-cells if they are IgE-positive
memory B-cells or at least activated B-cells [27]. Once
formed, the switched IgE-positive memory B-cells are
long-lived cells, but not all IgE responses lead to the
formation of IgE-positive memory B-cells [28]. The pres-
ent data suggest that the maturation of IgE-expressing B-
cells (activated or memory) to IgE-producing plasma cells
takes places in the nose. It is noteworthy that many of the
cytokines induced by allergen provocation such as IL-4,
IL-6 and IL-13 are also B-cell proliferation factors [11,
12, 29]. The nasal mucosa might also be the place of
maturation of B-cells. In the nasal mucosa are germinal
centres containing dendritic cells, T-cells and B-cells. The
availability of IL-4 and IL-13 produced in the nasal
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Fig. 3. ± Density of: a) immunoglobulin (Ig) E-positive B-cells; and b)
IgE-positive plasma cells in the nasal mucosa (lamina propria) of grass
pollen allergic patients (GP, n=11), perennial allergic patients (HDM; a)
n=16, b) n=12) and healthy controls (n=12). *: p<0.05; **: p<0.01.
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mucosa makes it possible for isotype switching of B-cells
to IgE-positive B-cells and proliferation and maturation
of B-cells to IgE-producing plasma cells to occur. More-
over, recent work done by the group of DURHAM et al. [17]
reports an increase in the number of B-cells expressing e
germ line transcripts locally in the nasal mucosa of hay
fever patients after allergen provocation. This increase in
e germ line transcripts could be suppressed by local
steroid treatment. Similar observations of isotype switch-
ing have been made by SAXON et al. [22] in nasal mucosal
cells. Not only T-cells but also mast cells and basophils
have the capacity to stimulate IgE synthesis by B-cells, as
producers of IL-4 and IL-13 and by the interaction of
mast cells CD154 (CD40 ligand) with B-cell CD40 [18,
30, 31]. The mast cell/basophilic induction and stimula-
tion of B-cell IgE-production indicate that immunoglo-
bulin switching, previously thought to take place only in
lymph node germinal centres, may also occur in peri-
pheral organs such as the nose. However, it is not clear
what impact this mast cell/B-cell interaction has on the
amount of IgE produced.
Comparing the present upper airway results with data
from the lower airways, CHVATCHKO et al. [32] describe
antigen-driven differentiation of B-cells via induction of a
follicular dendritic cell network in mice, with germinal
centres occurring in the parenchyma of inflamed lungs.
These germinal centres would then provide a local source
of immunoglobulin E-secreting plasma cells, contributing
to the release of factors mediating inflammatory proces-
ses in the lung [32]. Transplantation literature case reports
describe nonasthmatic recipients of asthmatic lungs who
develop asthma after transplantation; however, asthmatic
recipients of normal lungs do not develop asthma for up
to 3 yrs after transplantation. This supports the local char-
acteristic of lung disease in asthma, [33]. It is unclear
which portion of specific immunoglobulin E is produced
in the nasal mucosa of allergic rhinitis patients because
lymphoid tissues may also be involved in the production
of immunoglobulin E [4, 15, 34]. However, this study
clearly demonstrates that B-cells/plasma cells in the nasal
mucosa of allergic rhinitis patients produce (specific)
immunoglobulin E. This concurs with the hypothesis put
forward in the 1970s [1±3, 6].
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